Department of Pathology, Moti Lal Nehru Medical College, Lowther Road, Allahabad 211 001, India.
J Am Dent Assoc. 2010 Feb;141(2):151-6. doi: 10.14219/jada.archive.2010.0132.
ViziLite Plus with TBlue system (Zila Pharmaceuticals; now Zila, a division of Tolmar, Fort Collins, Colo.) and VELscope (LED Dental, White Rock, British Columbia, Canada) are oral cancer screening aids that have been developed to assist dentists in identifying precancerous and cancerous oral lesions.
The authors screened patients with an overhead examination light and then with VELscope or ViziLite. Patients with a clinically innocuous lesion underwent a biopsy, and the authors compared the results of tissue pathological analysis with findings from the screening aid tests to determine the sensitivity and specificity of each device. The authors tested these devices to determine their ability to aid in the decision-making process regarding whether further evaluation of a clinically innocuous lesion was required.
The authors examined 102 lesions with ViziLite and then biopsied them [corrected]. They found three dysplasias and one malignancy, none of which were detected with the ViziLite (sensitivity = 0 percent, confidence interval [CI] = 0-60.2 percent; specificity = 75.5 percent, CI = 66.7-82.8 percent). The authors examined another 156 lesions with VELscope and then biopsied them [corrected].They found 11 dysplasias and one malignancy, six of which were detected with VELscope (sensitivity = 50 percent, CI = 21.1-78.9 percent; specificity = 38.9 percent, CI = 30.8-46.9 percent).
The study results indicate that use of ViziLite or VELscope along with a conventional screening examination for lesions deemed clinically innocuous was not beneficial in identifying dysplasia or cancer. Additional clinical studies are needed before these devices can be recommended.
Clinicians and patients could have a false sense of security after obtaining a negative ViziLite or VELscope examination result because potentially large numbers of precancerous and cancerous lesions will be missed by both devices.
ViziLite Plus 与 TBlue 系统（Zila Pharmaceuticals；现为科罗拉多州柯林斯堡的 Tolmar 的一个部门）和 VELscope（加拿大不列颠哥伦比亚省白石的 LED Dental）是两种口腔癌筛查辅助工具，旨在帮助牙医识别癌前病变和癌性口腔病变。
作者使用头顶检查灯对患者进行初步筛查，然后使用 VELscope 或 ViziLite 进行检查。对临床无明显病变的患者进行活检，并将组织病理分析结果与筛查辅助工具测试结果进行比较，以确定每种设备的敏感性和特异性。作者测试了这些设备，以确定它们在辅助决策是否需要进一步评估临床无明显病变方面的能力。
作者用 ViziLite 检查了 102 处病变，然后对其进行了活检。他们发现了三个发育异常和一个恶性肿瘤，但 ViziLite 均未检测到（敏感性=0%，置信区间[CI]为 0-60.2%；特异性=75.5%，CI 为 66.7-82.8%）。作者用 VELscope 检查了另外 156 处病变，然后对其进行了活检。他们发现了 11 个发育异常和一个恶性肿瘤，但 VELscope 仅检测到其中 6 个（敏感性=50%，CI 为 21.1-78.9%；特异性=38.9%，CI 为 30.8-46.9%）。
研究结果表明，在对临床无明显病变的病变进行常规筛查检查的基础上，使用 ViziLite 或 VELscope 并不能有助于识别发育异常或癌症。在推荐这些设备之前，还需要进行更多的临床研究。
在获得 ViziLite 或 VELscope 的阴性检查结果后，临床医生和患者可能会产生一种虚假的安全感，因为这两种设备都会错过大量的癌前病变和癌症病变。
